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OBJECTIVES We sought to determine the incidence of and risk factors for thrombotic events early after
discontinuing antithrombin therapy in patients with acute coronary syndromes.
BACKGROUND Discontinuation of treatment with heparin and other thrombin inhibitors in patients with
unstable coronary syndromes has related to clinical and biochemical evidence of early
reactivation of thrombosis.
METHODS We studied 8,943 of the 12,142 patients with acute coronary syndromes enrolled in the
Global Use of Strategies To Open occluded arteries in acute coronary syndromes trial of
hirudin versus heparin. We excluded patients who received no study drug, lacked timing data,
died or had myocardial (re)infarction [(re)MI] during study-drug infusion, or began heparin
treatment within 2 h after treatment with the study drug was stopped. We assessed the
incidence and timing of (re)MI by type and timing of antithrombin treatment.
RESULTS In all, 215 patients (2.4%) suffered (re)MI, 49 within 12 h of antithrombin therapy
discontinuation and 166 between hour 12 and hospital discharge. The duration of infusion
did not differ between the hirudin and heparin groups. The rate of early re(MI) after drug
therapy discontinuation was significantly higher in patients given heparin versus hirudin
(0.8% vs. 0.3%, p 5 0.002). Patients with (re)MI had higher mortality at 30 days (23.6% vs.
2.4%, p 5 0.001) and 1 year (35.2% vs. 6.7%, p 5 0.001) compared with patients without
(re)MI.
CONCLUSIONS The incidence of (re)MI was clustered within 12 h of heparin therapy discontinuation, with
the greatest risk within 4 h. There was no evidence of early reactivation of thrombotic events
after hirudin. Patients who had (re)infarction had worse outcomes. Better understanding of
the mechanism and possible prevention of recurrent thrombosis is needed. (J Am Coll
Cardiol 2001;37:1001–7) © 2001 by the American College of Cardiology
Acute coronary syndromes are triggered by disruption of
atherosclerotic plaques with resultant activation of platelets
and the coagulation system. Given the central role of
platelets and thrombin in arterial thrombosis, heparin and
aspirin have become cornerstones of the treatment of
patients with acute coronary syndromes (1,2).
Although heparin has been widely used, it has several
limitations. These limitations include the inability of hep-
arin to inactivate thrombin bound to fibrin, the requirement
of antithrombin III as a cofactor and the neutralization of
heparin by circulating proteins, including platelet factor 4.
Consequently, the anticoagulant response to heparin varies
from patient to patient and requires careful monitoring.
Direct thrombin inhibitors, such as hirudin, overcome
several of these limitations of heparin. Hirudin inhibits
fibrin-bound thrombin and fluid-phase thrombin. Unlike
heparin, hirudin does not bind to plasma proteins and
results in a more predictable anticoagulant response (3).
Despite the promise of thrombin inhibitors, however, clin-
ical trials of hirudin have failed to show a clear and durable
advantage over heparin (4–6).
In addition, discontinuation of treatment with both
heparin (7–9) and thrombin inhibitors (10,11) is associated
with an increased short-term risk of thrombotic cardiac
events. Possible mechanisms involved in the reactivation of
thrombosis include a persistent active underlying prothrom-
botic state, transient hypercoagulability (“rebound”) as re-
flected by increased thrombin generation and activity after
treatment with thrombin inhibitors is stopped (12–16) or
both. Recently, investigators have tested different strategies
of heparin therapy discontinuation to prevent or attenuate
the rebound phenomenon, but without success (17).
The Global Use of Strategies To Open occluded arteries
in acute coronary syndromes (GUSTO-IIb) study provides
a unique opportunity to describe the clinical pattern of
myocardial (re)infarction [(re)MI] after discontinuation of
antithrombin therapy in a large cohort. We sought to
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investigate the frequency, timing and natural history of
(re)MI after discontinuing intravenous heparin and hirudin
therapy, and to determine whether different forms of anti-
coagulation influence the profile.
METHODS
Patient population. The GUSTO-IIb trial (5) compared
the efficacy of recombinant hirudin versus heparin in pa-
tients with acute coronary syndromes. To be eligible,
patients had to be within 12 h of chest pain onset and have
electrocardiographic (ECG) abnormalities of either ST-
segment elevation or depression of $0.05 mV or T-wave
inversion of $0.1 mV. Patients with a history of active
bleeding, serum creatinine .2.5 mg/dl, stroke within the
past year or a contraindication to heparin were excluded.
The study enrolled 12,142 patients, who were stratified by
the presence of ST-segment elevation. We excluded 197
patients who did not receive study drug, 304 patients who
lacked drug-timing information, 134 patients who died
before or during study-drug infusion, 232 who had (re)MI
during study-drug infusion and 2,668 in whom intravenous
heparin therapy was restarted within 2 h of study-drug
discontinuation. This left 8,943 patients for this analysis
(Fig. 1).
To compare the rates of in-hospital (re)MI during and
after study-drug infusion, however, we included the 122
patients who had (re)MI during infusion in a separate
population, for a total of 9,065 patients. Both analysis
populations were stratified by the occurrence and timing of
in-hospital (re)MI: none, (re)MI within 12 h after study
drug therapy was stopped, or (re)MI from 12 h after
treatment with the study drug was stopped to hospital
discharge.
Treatment. Patients with ST-segment elevation were eli-
gible to receive thrombolytic therapy of either accelerated
alteplase or streptokinase. All patients were randomly as-
signed to receive blinded heparin or recombinant hirudin.
Hirudin (desirudin) was given as an intravenous bolus of
0.1 mg/kg, followed by a continuous infusion of 0.1 mg/
kg/h. Heparin was given as an intravenous bolus of 5,000 U,
followed by a continuous infusion of 1,000 U/h. Both
infusions were maintained for 76 to 120 h.
Definition of (re)infarction. A blinded, independent ad-
judication committee reviewed and classified all suspected
(re)MIs. An MI was considered present at enrollment if the
creatine kinase (CK)-MB level was above normal (and $3%
of total CK) for samples at 0 h (baseline) or 8 h after
enrollment, or both. If the CK-MB was elevated only at the
16-h sample, and no symptoms had occurred between
enrollment and this time, the event also was considered an
MI at enrollment. If the CK-MB was elevated only at 16 h,
and symptoms consistent with MI had occurred after
enrollment, the review committee coded the event accord-
ing to data collected from the ECG, symptoms and enzyme
measurements. If CK-MB was unavailable, then total CK
was required to be .2 times the upper limit of normal. An
MI also was to be classified for new, significant Q-waves in
at least two contiguous leads.
For patients who had an MI before enrollment, a new MI
was defined as a rise in CK-MB to above-normal or to at
least twice the prior value (if it had been above the upper
limit), with appropriate signs, symptoms and ECG changes.
Statistical analysis. All analyses were performed using
SAS software (SAS, Cary, North Carolina). Prospectively
specified baseline and in-hospital variables were compared
among the analysis subgroups by means of the chi-square
test for trend for categorical variables and the Wilcoxon
rank-sum test for continuous variables. End points reviewed
by stratum were 30-day and one-year mortality. To compare
the (re)MI rates during versus after study-drug infusion, the
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
CK-MB 5 creatine kinase (-MB)
ECG 5 electrocardiographic
F1.2 5 prothrombin fragment 1.2
FRISC 5 FRagmin during InStability in Coronary
artery disease
GUSTO-I 5 Global Utilization of Streptokinase and
TPA (alteplase) for Occluded coronary
arteries
GUSTO-IIb 5 Global Use of Strategies To Open
occluded arteries in acute coronary
syndromes
OASIS 5 Organization to Assess Strategies for
Ischemic Syndromes
(re)MI 5 myocardial (re)infarction
TAT 5 thrombin-antithrombin III complex
TFPI 5 tissue-factor pathway inhibitor
TRIM 5 ThRombin Inhibition in Myocardial
ischemia
Figure 1. Derivation of study patient population, including comparison
subgroups for (re)infarction [(re)MI] rates.
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time “on” and “off” drug therapy was divided into 4-h
blocks. Each patient was observed until (re)MI or hospital
discharge. Patients with missing transfer or hospital dis-
charge data were assumed to be alive and were followed up
to 30 days.
The SAS GENMOD procedure was used to estimate
event rates for three drug-duration periods (0 h to ,12 h on
drug, 12 h to ,24 h on drug, and .24 h on drug), and four
such periods after drug therapy was stopped (0 to ,4 h off
drug, 4 to ,8 h off drug, 8 to ,12 h off drug and .12 h off
drug). We compared the (re)MI rate during study-drug
infusion with the rates during the first three 4-h blocks (that
is, the first 12 h postinfusion) because, from the Montreal
study (7) and Global Utilization of Streptokinase and TPA
(alteplase) for Occluded coronary arteries (GUSTO-I) trials
(8), this is when most reactivation events are thought to
occur.
RESULTS
Patient characteristics. Overall, 215 patients (2.4% of the
8,943 patients included in this analysis) suffered (re)MI
between study-drug discontinuation and hospital discharge
(Table 1). Of these, 49 (0.5%) occurred within 12 h after
treatment with study drug was stopped, and 166 (1.8%)
occurred between hour 12 and hospital discharge. Advanced
age, female gender, diabetes and prior nitrate use all were
significantly more common (p , 0.01) among patients
suffering (re)MI, and patients with early reinfarction tended
to have greater excess of these variables. ST segment
stratum, however, did not differ significantly by the occur-
rence of (re)MI.
Although the median activated partial thromboplastin
times (aPTTs) did not differ significantly between patients
with and without (re)MI at 12 and 24 h, they tended to be
higher among patients with late (re)MI. Likewise, no
differences were seen in the median aPTTs before study-
drug therapy discontinuation: 64 s for patients without
(re)MI, 60 s for patients with (re)MI within 12 h, and 64 s
for patients with reMI after 12 h (p 5 0.11).
Incidence and timing of (re)MI by antithrombin treat-
ment. In all, 97 patients in the hirudin group and 118 in
the heparin group suffered (re)MI after treatment with study
drug was stopped (2.2% vs. 2.7%, p 5 0.12) (Table 2). The
median time to (re)MI was 41 h (25th, 75th percentile, 18,
82 h) after hirudin therapy was stopped, and 34 h (9, 91 h)
Table 1. Baseline Characteristics
Myocardial (re)Infarction
Overall p Value*
None
(n 5 8,728)
<12 h
(n 5 49)
>12 h
(n 5 166)
Age (y) 64.3 (55, 72.3) 69.6 (63, 77.1) 67.7 (59.6, 77) 64.4 (55.1, 72.4) 0.0001
Male gender 70% 59% 62% 70% 0.008
Killip class 0.50
I or II 98.7% 97.9% 98.2% 98.7%
III or IV 1.3% 2.1% 1.8% 1.3%
Diabetes mellitus 17.2% 28.6% 23.5% 17.4% 0.007
Hypertension 44.8% 42.9% 50% 44.9% 0.25
Smoking status 0.06
Current 32.4% 18.4% 25.3% 32.2%
Previous 33.3% 42.9% 38% 33.4%
Never 34.4% 38.8% 36.8% 34.4%
Prior infarction 26.4% 32.7% 30.7% 26.5% 0.13
Prior angina 66% 75.5% 73.5% 66.2% 0.049
Prior oral beta-blocker use 61.9% 67.4% 63.9% 61.2% 0.57
Prior oral nitrate use 54.6% 63.3% 63.9% 54.8% 0.008
ST-segment stratum 0.49
ST elevation 33.5% 26.7% 35.5% 35.5%
No ST elevation 66.5% 63.3% 64.5% 66.5%
Thrombolytic use 27.3% 32.7% 27.7% 27.4% 0.70
Treatment 0.25
Hirudin 50.5% 28.6% 50% 50.4%
Heparin 49.5% 71.4% 50% 49.6%
Activated partial thromboplastin time (s)
12 h 68.8 (56.6, 85) 69 (53.9, 97) 73.8 (58, 91.7) 69 (56.6, 85.2) 0.08
24 h 64.2 (53.9, 77) 63.9 (51.4, 77) 67 (55, 76.7) 64.3 (54, 77) 0.34
Baseline platelet count (3109/L) 233 (195, 276) 242 (204, 270) 236.5 (194, 272) 237 (197, 272) 0.80
*Mantel-Haenszel test. Data are median (25th, 75th percentiles) or percentages.
Table 2. (re)Infarction by Antithrombotic Treatment
Hirudin
(n 5 4,509)
Heparin
(n 5 4,434)
No in-hospital (re)infarction 4,412 (97.9%) 4,316 (97.3%)
(re)Infarction ,12 h after drug
therapy discontinuation
14 (0.3%) 35 (0.8%)*
(re)Infarction $12 h after drug
therapy discontinuation
83 (1.8%) 83 (1.9%)
*p 5 0.002.
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after heparin therapy was stopped (p 5 0.14). The median
duration of infusion did not differ between the two groups
(72.6 h for hirudin vs. 72.8 h for heparin).
The occurrence and timing of (re)MI according to
administration of heparin and hirudin is shown in Figure 2.
During study-drug administration, there was a significantly
lower incidence of (re)MI with hirudin (5). During the 12 h
after discontinuation, patients who received heparin had
more (re)MIs than those given hirudin (35 of 4,434 [0.8%]
vs 14 of 4,509 [0.3%], p 5 0.002). From 12 h after
discontinuation until 120 h, there was a nonsignificant trend
toward more reinfarctions in the hirudin group.
The incidence of (re)MI per 4-h time interval, according
to drug treatment and time of study-drug administration, is
shown in Figure 3. During the first 24 h of infusion, the
incidence of (re)MI was lower with hirudin versus heparin.
The incidence of (re)MI increased somewhat during the
first 4 and 8 h after hirudin therapy discontinuation com-
Figure 2. Kaplan-Meier curves showing cumulative incidence of reinfarction in patients assigned to heparin (bold lines) or hirudin. (Left) Event rates
during study drug infusion until discontinuation. (Middle) Event rates after study drug therapy discontinuation until 12 h. (Right) Event rates in period
starting 12 h after antithrombin therapy discontinuation. At beginning of each period, event rates were (re) set at 0%. Any patient still alive contributes
to event estimates in each period.
Figure 3. Reinfarction rates per average 4-h time period in patients who received heparin (diamonds, solid lines) or hirudin (squares, dashed lines),
according to time relative to study drug infusion. Solid figures are point estimates; vertical lines are 95% confidence intervals.
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pared with during hirudin infusion (p 5 0.14). After
heparin therapy discontinuation, the incidence of (re)MI
increased by 5.8-fold during the first 4 h compared with
during the infusion, an increase that remained significant at
8 h (p 5 0.0001). There was a 0.5% absolute excess of
(re)MI in the first 8 h after discontinuing heparin therapy
compared with both the 8-h period before discontinuing
heparin therapy and the 8-h period after stopping hirudin
therapy.
Percutaneous coronary interventions. Similar propor-
tions of both treatment groups underwent percutaneous
intervention during study-drug infusion (8.5% for heparin;
9.4% for hirudin). Patients who underwent intervention
while receiving study drug had higher rates of (re)MI than
did patients who did not undergo intervention then. No
patient in either treatment group who underwent angio-
plasty during study-drug infusion had (re)MI within 12 h
after treatment with study drug was stopped; 2.1% and 1.4%
of patients suffered (re)MI beyond 12 h after drug therapy
was stopped in the hirudin and heparin groups, respectively.
Outcome and mortality. The hospital stay was signifi-
cantly longer for patients who suffered (re)MI compared
with those without (re)MI: 7 days for no (re)MI, 11 days for
(re)MI within 12 h and 13 days for (re)MI after 12 h (p 5
0.001). Patients with (re)MI had 10 times higher mortality
at 30 days compared with patients without (re)MI. Their
mortality remained significantly higher at 6 months and at
1 year (Table 3).
DISCUSSION
In the present study, we identified a clustering of (re)infarc-
tion after discontinuation of heparin infusion, with the
greatest risk in the first 4 to 8 h. Of every 200 patients who
had heparin therapy stopped after an acute coronary syn-
drome, one extra (re)MI occurred during the next 8 h
relative to the risk during treatment, or longer after treat-
ment. This early reactivation of thrombosis was not noted in
the hirudin-treated patients, although the overall rate of
(re)MI after stopping antithrombin treatment was similar
between groups. There was a nonsignificant excess of
(re)MI in the 5 days after discontinuation of hirudin
therapy, but whether reactivation does not occur, is blunted
or is delayed with hirudin compared with heparin is unclear.
Clinical and hematologic evidence for reactivation of
thrombosis. Reactivation of ischemic events in unstable
coronary syndromes has been shown after discontinuation of
heparin therapy. In the Montreal study (7), there was
recurrence of angina and MI in patients not given aspirin, at
a median 9.5 h after heparin therapy was stopped. Similarly,
in the GUSTO-I study (8), reinfarction was clustered
within 10 h of heparin therapy discontinuation; the greatest
risk was within 4 h. These patients had higher aPTT values,
however, suggesting that inadequate anticoagulation was
not the explanation. A persistent proaggregatory effect of
heparin on platelets may contribute to a prothrombotic state
(18). Granger et al. (9) reported that in a group of patients
with unstable angina receiving 325 mg of aspirin daily, both
thrombin activity (by fibrinopeptide A) and thrombin gen-
eration (by prothrombin fragment 1.2 [F1.2]) increased
after heparin therapy was stopped and then returned to
baseline at 24 h.
Direct antithrombin agents. The use of direct antithrom-
bin agents, which can inactivate clot-bound thrombin, does
not seem to prevent recurrence of angina after treatment
withdrawal. Gold et al. (15) showed that in patients with
acute coronary syndromes, the discontinuation of argatro-
ban therapy was associated with early recurrence of angina,
in most cases 4 to 8 h after cessation. There also was a
four-fold increase in the concentration of thrombin-
antithrombin III complex (TAT) at 2 h after infusion, but
no rebound in levels of fibrinopeptide A.
In the ThRombin Inhibition in Myocardial ischemia
(TRIM) study (11), the rates of death, MI and refractory
angina were increased during the first 24 h after 72 h of
heparin treatment, and with higher inogatran doses. This
reactivation seemed most pronounced in the heparin group,
was associated with increases in fibrin turnover and throm-
bin generation and continued after discontinuation.
The Organization to Assess Strategies for Ischemic
Syndromes (OASIS) pilot hemostasis substudy (19) com-
pared coagulation markers in patients treated with heparin
versus hirudin. During the infusion, no difference was seen
in the effect of heparin or hirudin on thrombin formation
(F1.2), but hirudin seemed to be more effective in the
suppression of markers of thrombin activity (TAT and
D-dimer). After treatment with study drug was stopped,
heparin-treated patients showed significant increases in
F1.2 and TAT concentrations, higher at 6 h. At 24 h after
stopping antithrombin therapy, the F 1.2 and TAT levels
had increased in the hirudin group, consistent with a
delayed rebound effect. These studies in aggregate show
clinical and hematologic evidence of reactivation of throm-
bosis after treatment with either heparin and direct throm-
bin inhibitors is stopped.
Reactivation in GUSTO-IIb. In the GUSTO-IIb hemo-
stasis substudy, there was no suppression effect on thrombin
formation (F1.2) for either heparin or hirudin during study
drug infusion. There was evidence of increased thrombin
activity, however, albeit delayed compared with heparin,
after discontinuation of hirudin therapy. These observa-
tions, and the results of our study, indicate that reactivation
of thrombotic events appears early in patients with acute
coronary syndromes when heparin therapy is discontinued.
Table 3. Mortality
Mortality
Myocardial (re)Infarction
p Value
None
(n 5 8,728)
<12 h
(n 5 49)
>12 h
(n 5 166)
30 days 211 (2.4%) 11 (22.5%) 41 (24.7%) 0.001
6 months 417 (4.9%) 17 (35.4%) 46 (27.9%) 0.001
1 year 544 (6.7%) 18 (39.1%) 50 (31.3%) 0.001
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Several important questions have arisen as a consequence.
One is whether early benefits of heparin could be better
sustained with long-term antithrombotic treatment. In the
FRagmin during InStability in Coronary artery disease
(FRISC) study of dalteparin (20), trends toward reactivation
occurred after the dose was reduced at 5 to 8 days and on
cessation of therapy after 41 days. In FRISC-II (21,22), the
initial benefit was sustained for at least 4 to 6 weeks with
dalteparin twice daily among patients treated noninvasively,
but there was some loss of benefit by 90 days. Although
there is some evidence of reactivation of thrombosis on
stopping treatment with low-molecular-weight heparin,
upstream inhibition of the coagulation cascade, with either
low-molecular-weight heparins (with higher anti-Xa to
anti-IIa activity) or with factor Xa inhibitors, might result in
less thrombin generation and therefore less reactivation of
thrombosis, upon therapy discontinuation (23). The use of
potent antiplatelet therapy also might prevent reactivation
after stopping heparin therapy.
Another question is whether patients undergoing early
percutaneous coronary intervention would have a lower risk
of reMI after treatment with antithrombin agents is
stopped, as suggested in FRISC-II, in which prolonged
treatment with dalteparin showed no trend toward benefit
for patients who had undergone revascularization. In
GUSTO-IIb, likewise, no patient in either treatment group
who had undergone angioplasty during study-drug infusion
had (re)MI in the 12 h after treatment with study drug was
stopped. The difference in reinfarction rates after study-
drug therapy discontinuation between patients who did and
did not undergo intervention was not significant, however,
perhaps related to the relatively small number of patients
who had undergone intervention while receiving study drug.
Whether gradual reductions in the dose of thrombin
inhibitor would prevent or attenuate this response also is
under question. Recently, Becker et al. (17) tested three
strategies for heparin therapy discontinuation. In a pilot
study, 30 patients with acute coronary syndromes treated
with intravenous heparin for 48 h were randomly assigned
to abrupt cessation, intravenous weaning over 12 h or
subcutaneous weaning over 12 h of abbreviated intravenous
weaning. Thrombin generation was evident within 1 h of
cessation, increased progressively (nearly doubling by 24 h)
and correlated inversely with the concentration of tissue-
factor pathway inhibitor (TFPI). The increase was greatest
among patients randomized to abrupt cessation and least in
those with intravenous weaning. The attenuated response
with intravenous weaning may relate to endothelial-cell
recovery and restoration of TFPI-mediated thromboresis-
tance.
The results of our study suggest that hirudin is associated
with less early reactivation of thrombosis than heparin,
perhaps reflecting a different mechanism of action on
thrombin, a longer half-life, or both.
Patients at heightened risk for early reinfarction after
stopping heparin therapy appear to be the same as those
generally at higher risk for reinfarction: the elderly, women,
diabetics and patients with prior angina. These high-risk
features likely reflect both more severe underlying vascular
disease and perhaps relative hypercoagulability.
A final question is whether measurement of markers of
inflammation during the initial evaluation could be used to
identify patients at risk of early thrombotic events and thus
higher mortality.
Study limitations. This study has several limitations. The
most important are those inherent to retrospective studies;
these findings thus should be considered hypothesis-
generating rather than definitive. In addition, heparin use
immediately after study-drug discontinuation accounted for
a large proportion of the patients excluded from the original
population (22%). The median age (64 vs. 65 years) and
proportions of patients who were female (31% vs. 30%) or
diabetic (17% vs. 19%) or had prior MI (27% vs. 26%) were
similar between the hirudin and heparin groups, suggesting
that this exclusion did not introduce systematic bias. An-
other issue is that we considered (re)infarction as the only
indicator of reactivation; we did not analyze the occurrence
of recurrent ischemia. Because recurrent ischemia was less
precisely defined, and only the first episode was collected,
our ability to define timing accurately was limited.
CONCLUSIONS
Although reactivation of ischemic events shortly after dis-
continuation of heparin or other antithrombin therapy has
been recognized, to our knowledge, this study is the largest
to address this important issue in patients with acute
coronary syndromes treated with concomitant aspirin.
There was no overall difference in reinfarction after stopping
heparin therapy versus hirudin. Our findings confirm, how-
ever, that clustering of (re)MI occurs early after heparin
therapy is stopped and suggest that this reactivation is
associated with a particularly poor prognosis. Prevention of
thrombotic reactivation may be an important target for
future antithrombotic strategies for patients with acute
coronary syndromes.
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